Tamar Hamosh Taddei, MD

Associate Professor of Medicine (Digestive Diseases)

Research Interests

Delivery of Health Care; Digestive System Diseases; Carcinoma, Hepatocellular; Translational Medical Research

Public Health Interests

Health Care Quality; Health Services Research

Research Organizations

Internal Medicine: Digestive Diseases: Lysosomal Disease & Inherited Metabolic Liver Disease Program | Liver Center

Faculty Research

Office of Cooperative Research

Research Summary

Dr. Taddei has built clinical programs at Yale and the VA with a focus on multidisciplinary, integrated care of the patient with liver cancer. In 2009, she developed the VA Connecticut Liver Tumor Board, now a regional tumor board serving VA Medical Centers in Connecticut, Providence, and Central Western Massachusetts. In 2011, she oversaw the accreditation of the Yale Liver Tumor Board, approved by the Smilow Cancer Hospital at Yale New Haven's Cancer Committee to meet all requirements of accreditation by the American College of Surgeons. She is funded by the VA National Center for Patient Safety and the VA Office of HIV, Hepatitis and Related Conditions Programs for national implementation of the Cancer Care Tracking System, a locally developed tool to improve liver cancer detection and comprehensive care. She is co-Principal Investigator on a national VA study of outcomes in Veterans with liver cancer. She collaborates on several translational projects that seek to understand the biology of liver cancer to inform prognosis and targets for treatment.

Specialized Terms: Clinical, translational, and outcome research on hepatocellular carcinoma

Selected Publications

  • Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis. Langberg KM, Taddei TH. “Balancing quality with quantity: The role of palliative care in managing decompensated cirrhosis.” Hepatology. 2016;64(4):1014-6.
  • Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. b. Goldberg DS, Taddei TH, Serper M, Mehta R, Dieperink E, Aytaman A, Baytarian M, Fox R, Hunt K, Pedrosa M, Pocha C, Valderrama A, Kaplan DE. Identifying barriers to hepatocellular carcinoma surveillance in a national sample of patients with cirrhosis. Hepatology. 2016 [Epub ahead of print] PMID:. 27531119
  • Recalibrating the Child-Turcotte-Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis a. Kaplan DE, Dai F, Skanderson M, Aytaman A, Baytarian M, D'Addeo K, Fox R, Hunt K, Knott A, Mehta R, Pedrosa M, Pocha C, Valderrama A, Taddei T; VOCAL Study Group. Recalibrating the Child-Turcotte-Pugh Score to Improve Prediction of Transplant-Free Survival in Patients with Cirrhosis. Dig Dis Sci. 2016; 61:3309-3320. PMID: 27405990
  • HIV, Aging, and Viral Coinfections: Taking the Long View. Taddei TH, Lo Re V 3rd, Justice AC. HIV, Aging, and Viral Coinfections: Taking the Long View. Curr HIV/AIDS Rep. 2016;13(5):269-78.
  • Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma? Taddei TH. Learning from the Melbourne experience: How reliable are cancer registry data for hepatocellular carcinoma? Hepatology 2016; 63(4):1078-9.
  • Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score from a National Electronic Healthcare Database. c. Kaplan DE, Dai F, Aytaman A, Baytarian M, Fox R, Hunt K, Knott A, Pedrosa M, Pocha C, Mehta R, Duggal M, Skanderson M, Valderrama A, Taddei TH; VOCAL Study Group. Development and Performance of an Algorithm to Estimate the Child-Turcotte-Pugh Score from a National Electronic Healthcare Database. Clin Gastroenterol Hepatol. 2015: 2015 Dec;13(13):2333-41.e1-6. PMID: 26188137.
  • Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. c. Vilarinho S. and Taddei T. Therapeutic strategies for hepatocellular carcinoma: new advances and challenges. Curr Treat Options Gastroenterol. 2015:13(2):219-34. PMID: 25791207.
  • A multidisciplinary approach: group dynamics Taddei TH. A multidisciplinary approach: group dynamics. J Clin Gastroenterol 2013; S27-9.
  • Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism

    Mistry PK, Taddei T, vom Dahl S, Rosenbloom BE. Gaucher disease and malignancy: a model for cancer pathogenesis in an inborn error of metabolism. Crit Rev Oncog 2013; 18:235-46

  • Hepatocellular Carcinoma – Diagnosis and Treatment Taddei TH. Chapter 53: Hepatocellular Carcinoma – Diagnosis and Treatment. In: Oncology for the Primary Care Provider. Rose MG, DeVita VT, Lawrence TS, and Rosenberg SA, Eds. Lippincott, Williams and Wilkins 2012.
  • Hepatocellular Carcinoma – Screening and Surveillance Taddei TH. Chapter 14: Hepatocellular Carcinoma – Screening and Surveillance. In: Oncology for the Primary Care Provider. Rose MG, DeVita VT, Lawrence TS, and Rosenberg SA, Eds. Lippincott, Williams and Wilkins 2012.
  • VA Connecticut Healthcare System improves cancer care: case management and a web-based tracking system are used to improve access and quality. Vogel DC, Connery DM, DeLorenzo AL, Ebbert MH, Garcia-Tsao G, Hunnibel LS, Rosa M, Rose MG, Taddei, TH, Taylor CR. VA Connecticut Healthcare System improves cancer care: case management and a web-based tracking system are used to improve access and quality. CMSA Today. 2012; 6:8-11.
  • Managing hepatocellular carcinoma through multidisciplinary care. Fox RK, Taddei T, Rose MG. Managing hepatocellular carcinoma through multidisciplinary care. Federal Practitioner 2010; 27 (suppl 10):1-6.
  • Managing advanced hepatocellular carcinoma. Multidisciplinary perspectives on management: a roundtable discussion Monto A, Kohlwes J, Raval GR, Mehta P, El-Serag HB, Taddei T. Managing advanced hepatocellular carcinoma. Multidisciplinary perspectives on management: a roundtable discussion. Federal Practitioner 2009; 26 (suppl 1):20-24.
  • Managing advanced hepatocellular carcinoma: treating unresectable disease. Taddei T. Managing advanced hepatocellular carcinoma: treating unresectable disease. Federal Practitioner 2009; 26 (suppl 1):15-19.

Full List of PubMed Publications

Edit this profile

Contact Info

Tamar Hamosh Taddei, MD
Mailing Address
PO Box 208019
333 Cedar Street

New Haven, CT 06520-8019